The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.
Data from Gilead's Atlas combination trial in Nash could point to a way forward, while Roche and Ionis are hoping to confirm earlier signals seen with a…
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.
Wave will soon report key early-stage data with its exon-skipping DMD candidate suvodirsen but, unlike Sarepta, the group is starting its confirmatory trial before…
The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.